U.S.-based Biomarin Pharmaceutical Inc.’s treatment for one of the most common forms of dwarfism received clearance from the European Commission, becoming the first therapy to get an approval in the region for achondroplasia.

The Food and Drug Administration on Aug. 23 approved Cara Therapeutics’ drug to treat moderate-to-severe itching in patients with chronic kidney disease undergoing dialysis, making Korsuva the first therapy for the ailment in the United States.

President Joe Biden on Aug. 12 called on U.S. lawmakers to enact legislation aimed at lowering drug prices, including allowing Medicare to negotiate drug prices and imposing penalties on drugmakers that hike prices faster than inflation.

The U.S. Veterans Health Administration will not include Aduhelm, the $56,000-a-year Alzheimer’s drug made by Biogen Inc. and Eisai Co. Ltd., on the VHA’s list of approved products due to a lack of evidence that the medicine is effective as well as safety concerns, the agency said on Aug. 11.

The House Committee on Oversight and Reform announced plans to investigate the approval and pricing of Biogen’s Alzheimer’s disease medicine Aduhelm (aducanumab), which has a list price of $56,000 per year.

The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals Inc.’s Trikafta to treat cystic fibrosis in children aged 6 to 11 years old, making the cocktail therapy the first approved treatment for CF in that age group.

Billionaire entrepreneur Mark Cuban – best known as the owner of the Dallas Mavericks and an investor on the ABC business reality series “Shark Tank” – is diving into generic drugs with a new startup, dubbed Mark Cuban Cost Plus Drug Company.

At the start of 2021, 70 companies raised the price of hundreds of prescription drugs by an average of 3.3%.

The Coalition for Healthcare Communication will present a special post-election webinar on Nov. 19 featuring Kate Rawson – senior editor of Prevision Policy and an experienced, well-connected inside-the-beltway observer – with a more in-depth look at implications of the 2020 elections for healthcare policy.

Novartis said new interim data from an ongoing phase clinical trial for the company’s $2.1 million-per-patient gene therapy Zolgensma showed spinal muscular atrophy patients experienced significant therapeutic benefit.